Global Oral Drugs for Benign Prostatic Hyperplasia Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Page: 105

Published Date: 06 Aug 2022

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Oral Drugs for Benign Prostatic Hyperplasia market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Oral Drugs for Benign Prostatic Hyperplasia market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.

The Oral Drugs for Benign Prostatic Hyperplasia market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.

Hospitals occupied for % of the Oral Drugs for Benign Prostatic Hyperplasia global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Alpha Blockers segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Key Features of This Report:
This report provides in-depth analysis of the global Oral Drugs for Benign Prostatic Hyperplasia market, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year
Main Oral Drugs for Benign Prostatic Hyperplasia manufacturers’ industry ranking, sales, revenue, price, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This reports profiles key players in the global Oral Drugs for Benign Prostatic Hyperplasia market based on the following parameters – headquarters, production locations, products portfolio, Oral Drugs for Benign Prostatic Hyperplasia revenue, sales, average price and gross margin, recent developments.

Evaluation and forecast the Oral Drugs for Benign Prostatic Hyperplasia market size, projected growth trends, and corresponding market share analysis by type, by application, and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market Segmentation
Oral Drugs for Benign Prostatic Hyperplasia market is split by Type and by Application. For the period 2017-2028, the growth among segments provides accurate calculations and forecasts for sales by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type (2017-2028; USD Million)
    Alpha Blockers
    5-alpha Reductase Inhibitors
    Others

Market segment by Application (2017-2028; USD Million)
    Hospitals
    Drugstores
    Others

The key market players for global Oral Drugs for Benign Prostatic Hyperplasia market are listed below:
    Eli Lilly
    GlaxoSmithKline
    Astellas Pharma
    Sanofi
    Pfizer
    Abbott
    Allergan
    TEVA
    Viatris
    Novartis
    Merck

Region Segment (2017-2028; USD Million)
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Drugs for Benign Prostatic Hyperplasia product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, with price, sales, revenue and global market share of Oral Drugs for Benign Prostatic Hyperplasia from 2019 to 2022.
Chapter 3, the Oral Drugs for Benign Prostatic Hyperplasia competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Drugs for Benign Prostatic Hyperplasia breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Oral Drugs for Benign Prostatic Hyperplasia market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oral Drugs for Benign Prostatic Hyperplasia.
Chapter 13, 14, and 15, to describe Oral Drugs for Benign Prostatic Hyperplasia sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Oral Drugs for Benign Prostatic Hyperplasia Introduction
    1.2 Market Analysis by Type
        1.2.1 Overview: Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Alpha Blockers
        1.2.3 5-alpha Reductase Inhibitors
        1.2.4 Others
    1.3 Market Analysis by Application
        1.3.1 Overview: Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Hospitals
        1.3.3 Drugstores
        1.3.4 Others
    1.4 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size & Forecast
        1.4.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Value (2017 & 2021 & 2028)
        1.4.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume (2017-2028)
        1.4.3 Global Oral Drugs for Benign Prostatic Hyperplasia Price (2017-2028)
    1.5 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity Analysis
        1.5.1 Global Oral Drugs for Benign Prostatic Hyperplasia Total Production Capacity (2017-2028)
        1.5.2 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity by Geographic Region
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
        1.6.2 Oral Drugs for Benign Prostatic Hyperplasia Market Restraints
        1.6.3 Oral Drugs for Benign Prostatic Hyperplasia Trends Analysis

2 Manufacturers Profiles
    2.1 Eli Lilly
        2.1.1 Eli Lilly Details
        2.1.2 Eli Lilly Major Business
        2.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.2 GlaxoSmithKline
        2.2.1 GlaxoSmithKline Details
        2.2.2 GlaxoSmithKline Major Business
        2.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.3 Astellas Pharma
        2.3.1 Astellas Pharma Details
        2.3.2 Astellas Pharma Major Business
        2.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.4 Sanofi
        2.4.1 Sanofi Details
        2.4.2 Sanofi Major Business
        2.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.5 Pfizer
        2.5.1 Pfizer Details
        2.5.2 Pfizer Major Business
        2.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.6 Abbott
        2.6.1 Abbott Details
        2.6.2 Abbott Major Business
        2.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.7 Allergan
        2.7.1 Allergan Details
        2.7.2 Allergan Major Business
        2.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.8 TEVA
        2.8.1 TEVA Details
        2.8.2 TEVA Major Business
        2.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.9 Viatris
        2.9.1 Viatris Details
        2.9.2 Viatris Major Business
        2.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.10 Novartis
        2.10.1 Novartis Details
        2.10.2 Novartis Major Business
        2.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    2.11 Merck
        2.11.1 Merck Details
        2.11.2 Merck Major Business
        2.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        2.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Oral Drugs for Benign Prostatic Hyperplasia Breakdown Data by Manufacturer
    3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
    3.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Manufacturer (2019, 2020, 2021, and 2022)
    3.3 Key Manufacturer Market Position in Oral Drugs for Benign Prostatic Hyperplasia
    3.4 Market Concentration Rate
        3.4.1 Top 3 Oral Drugs for Benign Prostatic Hyperplasia Manufacturer Market Share in 2021
        3.4.2 Top 6 Oral Drugs for Benign Prostatic Hyperplasia Manufacturer Market Share in 2021
    3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity by Company: 2021 VS 2022
    3.6 Manufacturer by Geography: Head Office and Oral Drugs for Benign Prostatic Hyperplasia Production Site
    3.7 New Entrant and Capacity Expansion Plans
    3.8 Mergers & Acquisitions

4 Market Analysis by Region
    4.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region
        4.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Region (2017-2028)
        4.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2028)
    4.2 North America Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028)
    4.3 Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028)
    4.4 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028)
    4.5 South America Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028)
    4.6 Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028)

5 Market Segment by Type
    5.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Type (2017-2028)
    5.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2017-2028)
    5.3 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Type (2017-2028)

6 Market Segment by Application
    6.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Application (2017-2028)
    6.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2017-2028)
    6.3 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Application (2017-2028)

7 North America by Country, by Type, and by Application
    7.1 North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2028)
    7.2 North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2028)
    7.3 North America Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country
        7.3.1 North America Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Country (2017-2028)
        7.3.2 North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2028)
        7.3.3 United States Market Size and Forecast (2017-2028)
        7.3.4 Canada Market Size and Forecast (2017-2028)
        7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application
    8.1 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2028)
    8.2 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2028)
    8.3 Europe Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country
        8.3.1 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Country (2017-2028)
        8.3.2 Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2028)
        8.3.3 Germany Market Size and Forecast (2017-2028)
        8.3.4 France Market Size and Forecast (2017-2028)
        8.3.5 United Kingdom Market Size and Forecast (2017-2028)
        8.3.6 Russia Market Size and Forecast (2017-2028)
        8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application
    9.1 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2028)
    9.2 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2028)
    9.3 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region
        9.3.1 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Region (2017-2028)
        9.3.2 Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2028)
        9.3.3 China Market Size and Forecast (2017-2028)
        9.3.4 Japan Market Size and Forecast (2017-2028)
        9.3.5 Korea Market Size and Forecast (2017-2028)
        9.3.6 India Market Size and Forecast (2017-2028)
        9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
        9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application
    10.1 South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2028)
    10.2 South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2028)
    10.3 South America Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country
        10.3.1 South America Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Country (2017-2028)
        10.3.2 South America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2028)
        10.3.3 Brazil Market Size and Forecast (2017-2028)
        10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application
    11.1 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2028)
    11.2 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2028)
    11.3 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country
        11.3.1 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales in Volume by Country (2017-2028)
        11.3.2 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2028)
        11.3.3 Turkey Market Size and Forecast (2017-2028)
        11.3.4 Egypt Market Size and Forecast (2017-2028)
        11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
        11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain
    12.1 Raw Material of Oral Drugs for Benign Prostatic Hyperplasia and Key Manufacturers
    12.2 Manufacturing Costs Percentage of Oral Drugs for Benign Prostatic Hyperplasia
    12.3 Oral Drugs for Benign Prostatic Hyperplasia Production Process
    12.4 Oral Drugs for Benign Prostatic Hyperplasia Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers
    13.1 Sales Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
    13.2 Oral Drugs for Benign Prostatic Hyperplasia Typical Distributors
    13.3 Oral Drugs for Benign Prostatic Hyperplasia Typical Customers

14 Research Findings and Conclusion

15 Appendix
    15.1 Methodology
    15.2 Research Process and Data Source
    15.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type, (USD Million), 2017 & 2021 & 2028
    Table 2. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application, (USD Million), 2017 & 2021 & 2028
    Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 4. Eli Lilly Major Business
    Table 5. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 6. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
    Table 8. GlaxoSmithKline Major Business
    Table 9. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 10. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 11. Astellas Pharma Basic Information, Manufacturing Base and Competitors
    Table 12. Astellas Pharma Major Business
    Table 13. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 14. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 15. Sanofi Basic Information, Manufacturing Base and Competitors
    Table 16. Sanofi Major Business
    Table 17. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 18. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 20. Pfizer Major Business
    Table 21. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 22. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 23. Abbott Basic Information, Manufacturing Base and Competitors
    Table 24. Abbott Major Business
    Table 25. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 26. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 27. Allergan Basic Information, Manufacturing Base and Competitors
    Table 28. Allergan Major Business
    Table 29. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 30. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 31. TEVA Basic Information, Manufacturing Base and Competitors
    Table 32. TEVA Major Business
    Table 33. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 34. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 35. Viatris Basic Information, Manufacturing Base and Competitors
    Table 36. Viatris Major Business
    Table 37. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 38. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 39. Novartis Basic Information, Manufacturing Base and Competitors
    Table 40. Novartis Major Business
    Table 41. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 42. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 43. Merck Basic Information, Manufacturing Base and Competitors
    Table 44. Merck Major Business
    Table 45. Merck Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 46. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 47. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
    Table 48. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
    Table 49. Market Position of Manufacturers in Oral Drugs for Benign Prostatic Hyperplasia, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
    Table 50. Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity by Company, (K Units): 2020 VS 2021
    Table 51. Head Office and Oral Drugs for Benign Prostatic Hyperplasia Production Site of Key Manufacturer
    Table 52. Oral Drugs for Benign Prostatic Hyperplasia New Entrant and Capacity Expansion Plans
    Table 53. Oral Drugs for Benign Prostatic Hyperplasia Mergers & Acquisitions in the Past Five Years
    Table 54. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2017-2022) & (K Units)
    Table 55. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2023-2028) & (K Units)
    Table 56. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2022) & (USD Million)
    Table 57. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2023-2028) & (USD Million)
    Table 58. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 59. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 60. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2017-2022) & (USD Million)
    Table 61. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2023-2028) & (USD Million)
    Table 62. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Type (2017-2022) & (US$/Unit)
    Table 63. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Type (2023-2028) & (US$/Unit)
    Table 64. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 65. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 66. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2017-2022) & (USD Million)
    Table 67. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2023-2028) & (USD Million)
    Table 68. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Application (2017-2022) & (US$/Unit)
    Table 69. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Application (2023-2028) & (US$/Unit)
    Table 70. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
    Table 71. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2023-2028) & (K Units)
    Table 72. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & (USD Million)
    Table 73. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2023-2028) & (USD Million)
    Table 74. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 75. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 76. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 77. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 78. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
    Table 79. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2023-2028) & (K Units)
    Table 80. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & (USD Million)
    Table 81. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2023-2028) & (USD Million)
    Table 82. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 83. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 84. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 85. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 86. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2017-2022) & (K Units)
    Table 87. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2023-2028) & (K Units)
    Table 88. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2022) & (USD Million)
    Table 89. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2023-2028) & (USD Million)
    Table 90. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 91. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 92. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 93. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 94. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
    Table 95. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2023-2028) & (K Units)
    Table 96. South America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & (USD Million)
    Table 97. South America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2023-2028) & (USD Million)
    Table 98. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 99. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 100. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 101. South America Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 102. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2017-2022) & (K Units)
    Table 103. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2023-2028) & (K Units)
    Table 104. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2022) & (USD Million)
    Table 105. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2023-2028) & (USD Million)
    Table 106. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
    Table 107. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2023-2028) & (K Units)
    Table 108. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
    Table 109. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2023-2028) & (K Units)
    Table 110. Oral Drugs for Benign Prostatic Hyperplasia Raw Material
    Table 111. Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia Raw Materials
    Table 112. Direct Channel Pros & Cons
    Table 113. Indirect Channel Pros & Cons
    Table 114. Oral Drugs for Benign Prostatic Hyperplasia Typical Distributors
    Table 115. Oral Drugs for Benign Prostatic Hyperplasia Typical Customers
List of Figures
    Figure 1. Oral Drugs for Benign Prostatic Hyperplasia Picture
    Figure 2. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type in 2021
    Figure 3. Alpha Blockers
    Figure 4. 5-alpha Reductase Inhibitors
    Figure 5. Others
    Figure 6. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application in 2021
    Figure 7. Hospitals
    Figure 8. Drugstores
    Figure 9. Others
    Figure 10. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
    Figure 11. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue and Forecast (2017-2028) & (USD Million)
    Figure 12. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (2017-2028) & (K Units)
    Figure 13. Global Oral Drugs for Benign Prostatic Hyperplasia Price (2017-2028) & (US$/Unit)
    Figure 14. Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity (2017-2028) & (K Units)
    Figure 15. Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity by Geographic Region: 2022 VS 2028
    Figure 16. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
    Figure 17. Oral Drugs for Benign Prostatic Hyperplasia Market Restraints
    Figure 18. Oral Drugs for Benign Prostatic Hyperplasia Market Trends
    Figure 19. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Manufacturer in 2021
    Figure 20. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Manufacturer in 2021
    Figure 21. Oral Drugs for Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
    Figure 22. Top 3 Oral Drugs for Benign Prostatic Hyperplasia Manufacturer (Revenue) Market Share in 2021
    Figure 23. Top 6 Oral Drugs for Benign Prostatic Hyperplasia Manufacturer (Revenue) Market Share in 2021
    Figure 24. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2028)
    Figure 25. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2017-2028)
    Figure 26. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028) & (USD Million)
    Figure 27. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028) & (USD Million)
    Figure 28. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028) & (USD Million)
    Figure 29. South America Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028) & (USD Million)
    Figure 30. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue (2017-2028) & (USD Million)
    Figure 31. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2028)
    Figure 32. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2017-2028)
    Figure 33. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Type (2017-2028) & (US$/Unit)
    Figure 34. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 35. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2017-2028)
    Figure 36. Global Oral Drugs for Benign Prostatic Hyperplasia Price by Application (2017-2028) & (US$/Unit)
    Figure 37. North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2028)
    Figure 38. North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 39. North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2028)
    Figure 40. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2028)
    Figure 41. United States Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 42. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 43. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 44. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2028)
    Figure 45. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 46. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2028)
    Figure 47. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2028)
    Figure 48. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 49. France Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 50. United Kingdom Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 51. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 53. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2028)
    Figure 54. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 55. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2028)
    Figure 56. Asia-Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2017-2028)
    Figure 57. China Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 59. Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. India Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. Australia Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. South America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2028)
    Figure 64. South America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 65. South America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2028)
    Figure 66. South America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2028)
    Figure 67. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 68. Argentina Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2028)
    Figure 70. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2028)
    Figure 71. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2028)
    Figure 72. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2017-2028)
    Figure 73. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Egypt Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 75. Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 76. South Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 77. Manufacturing Cost Structure Analysis of Oral Drugs for Benign Prostatic Hyperplasia in 2021
    Figure 78. Manufacturing Process Analysis of Oral Drugs for Benign Prostatic Hyperplasia
    Figure 79. Oral Drugs for Benign Prostatic Hyperplasia Industrial Chain
    Figure 80. Sales Channel: Direct Channel vs Indirect Channel
    Figure 81. Methodology
    Figure 82. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck

Related Reports

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 06 Feb 2023

date Pharma & Healthcare

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2023-2029

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2023-2029

date 04 Feb 2023

date Pharma & Healthcare

The global Oral Drugs for Benign Prostatic Hyperplasia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 05 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Oral Drugs for Benign Prostatic Hyperplasia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2024-2030

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2024-2030

date 25 Feb 2024

date Pharma & Healthcare

The global Oral Drugs for Benign Prostatic Hyperplasia market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

oral drugs for benign prostatic hyperplasia

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>